Loading...
During the past decade, clinicians have become reacquainted with colistin, a venerable antibiotic that was shelved for years because of its toxicity profile and then resurrected to combat multidrug-resistant gram-negative rods (JW Gen Med Jun 3 2003). Now, the time has come to assess recent experience with this drug.
Researchers compiled results from 20 studies published between 2003 and early 2011 on the use of intravenous or aerosolized colistin for the treatment of ventilator-associated pneumonia (VAP). A meta-analysis of the six studies of colistin as replacement or adjunctive therapy compared with standard care revealed no significant differences in clinical response, mortality, length of intensive care unit (ICU) stay, nephrotoxicity, …